Session » Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM

Abstract Number: 0112

A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics

8:30AM-10:30AM

Abstract Number: 0107

Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries

8:30AM-10:30AM

Abstract Number: 0104

Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population

8:30AM-10:30AM

Abstract Number: 0085

Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes

8:30AM-10:30AM

Abstract Number: 0094

Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City

8:30AM-10:30AM

Abstract Number: 0092

Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City

8:30AM-10:30AM

Abstract Number: 0109

COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

8:30AM-10:30AM

Abstract Number: 0106

COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study

8:30AM-10:30AM

Abstract Number: 0116

COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease

8:30AM-10:30AM

Abstract Number: 0084

COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab

8:30AM-10:30AM

Abstract Number: 0102

Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients

8:30AM-10:30AM

Abstract Number: 0108

Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

8:30AM-10:30AM

Abstract Number: 0088

Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data

8:30AM-10:30AM

Abstract Number: 0099

First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)

8:30AM-10:30AM

Abstract Number: 0117

Flares Following Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States

8:30AM-10:30AM

Abstract Number: 0101

Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States

8:30AM-10:30AM

Abstract Number: 0110

Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry

8:30AM-10:30AM

Abstract Number: 0105

Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization

8:30AM-10:30AM

Abstract Number: 0097

Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors

8:30AM-10:30AM

Abstract Number: 0098

Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission

8:30AM-10:30AM

Abstract Number: 0103

Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study

8:30AM-10:30AM

Abstract Number: 0113

Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease

8:30AM-10:30AM

Abstract Number: 0115

Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020

8:30AM-10:30AM

Abstract Number: 0095

Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City

8:30AM-10:30AM

Abstract Number: 0111

Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study

8:30AM-10:30AM

Abstract Number: 0100

Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey

8:30AM-10:30AM

Abstract Number: 0086

SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review

8:30AM-10:30AM

Abstract Number: 0089

SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls

8:30AM-10:30AM

Abstract Number: 0090

Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial

8:30AM-10:30AM

Abstract Number: 0093

The Association of General and Covid-19-Specific Stress with Changes in Patient-Reported Outcomes and Comorbidities

8:30AM-10:30AM

Abstract Number: 0114

The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases

8:30AM-10:30AM

Abstract Number: 0096

The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study

8:30AM-10:30AM

Abstract Number: 0087

TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries

8:30AM-10:30AM

Abstract Number: 0091

Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort